Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRXB.L Regulatory News (RXB)

  • There is currently no data for RXB

Directors Interests

27 Sep 2016 13:00

RNS Number : 9706K
Rex Bionics PLC
27 September 2016
 

Rex Bionics plc

("Rex Bionics" or the "Company")

 

Directors Interests

 

27 September 2016 Rex Bionics plc (AIM: RXB),  the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, announces that pursuant to the existing Deferred Bonus Share Plan (under which employees are issued options to subscribe for cash at par for Ordinary Shares in respect of the bonus to which they were otherwise entitled) the Company has made awards, for the financial year ended 31 March 2016, in respect of an aggregate of 791,279 Ordinary Shares of 10p each in the Company ("Ordinary Shares") (representing 3.1% of the current issued Ordinary Shares) to certain employees in the Company including the Chief Executive Officer, the Chief Financial Officer and the Chief Technology Officer.

The Awards to those Directors are as follows:

Name

Deferred Bonus Award Shares

 

Crispin SimonChief Executive Officer

140,000

 

Peter WorrallChief Financial Officer

93,333

Richard LittleChief Technology Officer

134,070

 

 

For further information please contact:

 

Rex Bionics Plc

Peter Worrall, Chief Financial Officer

+44 (0) 142 864 5416

 

Stifel Securities Limited (NOMAD and Broker)

Jonathan Senior, Stewart Wallace, Ben Maddison

+44 (0) 20 7710 7600

 

Consilium Strategic Communications

Lindsey Neville

rexbionics@consilium-comms.com

+44 (0) 203 709 5700

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.

Details of the person discharging managerial responsibilities/person closely associated

(a)

Name: CRISPIN SIMON

 

2.

 

Reason for the notification

(a)

Position/status: CHIEF EXECUTIVE

(b)

Initial notification/Amendment: INITIAL

 

3.

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

(a)

Name: REX BIONICS plc

(b)

LEI: NA

 

4.

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

(a)

Description of the Financial instrument, type of instrument: Rex Bionics Option over Ordinary Shares of 10p each

Identification code: ISIN: GB00BLRLQM66

(b)

Nature of the transaction: Issue of awards under Deferred Bonus Share Plan

(c)

Price(s) and volume(s)

Price(s): 10p per Ordinary Share

Volume(s): 140,000

(d)

Aggregated information

· Aggregated volume: 140,000 Ordinary Shares awarded

· Price: Exercise price: 10p per Ordinary Share

 

(e)

Date of the transaction: 27 September 2016

(f)

Place of the transaction: London Stock Exchange - AIM

 

 

 

1.

Details of the person discharging managerial responsibilities/person closely associated

(a)

Name: PETER WORRALL

 

2.

 

Reason for the notification

(a)

Position/status: CHIEF FINANCIAL OFFICER

(b)

Initial notification/Amendment: INITIAL

 

3.

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

(a)

Name: REX BIONICS plc

(b)

LEI: NA

 

4.

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

(a)

Description of the Financial instrument, type of instrument: Rex Bionics Option over Ordinary Shares of 10p each

Identification code: ISIN: GB00BLRLQM66

(b)

Nature of the transaction: Issue of awards under Deferred Bonus Share Plan

(c)

Price(s) and volume(s)

Price(s): 10p per Ordinary Share

Volume(s): 93,333

(d)

Aggregated information

· Aggregated volume: 93,333 Ordinary Shares awarded

· Price: Exercise price: 10p per Ordinary Share

 

(e)

Date of the transaction: 27 September 2016

(f)

Place of the transaction: London Stock Exchange - AIM

 

 

1.

Details of the person discharging managerial responsibilities/person closely associated

(a)

Name: RICHARD LITTLE

 

2.

 

Reason for the notification

(a)

Position/status: CHIEF TECHNOLOGY OFFICER

(b)

Initial notification/Amendment: INITIAL

 

3.

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

(a)

Name: REX BIONICS plc

(b)

LEI: NA

 

4.

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

(a)

Description of the Financial instrument, type of instrument: Rex Bionics Option over Ordinary Shares of 10p each

Identification code: ISIN: GB00BLRLQM66

(b)

Nature of the transaction: Issue of awards under Deferred Bonus Share Plan

(c)

Price(s) and volume(s)

Price(s): 10p per Ordinary Share

Volume(s): 134,070

(d)

Aggregated information

· Aggregated volume: 134,070 Ordinary Shares awarded

· Price: Exercise price: 10p per Ordinary Share

 

(e)

Date of the transaction: 27 September 2016

(f)

Place of the transaction: London Stock Exchange - AIM

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHLLFELATIDFIR
12
Date   Source Headline
30th May 20177:30 amRNSSuspension - Rex Bionics Plc
26th May 20174:31 pmRNSHolding(s) in Company
26th May 20177:00 amRNSCompletion of Business Transfer & Refinancing
25th May 201710:39 amRNSHoldings in Company
25th May 201710:38 amRNSHoldings in Company
22nd May 201712:23 pmRNSResults of General Meeting
3rd May 20177:00 amRNSRestructuring and New Investment
13th Mar 20177:00 amRNSFunding and strategic review update
23rd Jan 20177:00 amRNSREX initiates RAPPER III MS clinical trial
5th Dec 20167:00 amRNSInterim Results for six months ending 30 Sept 2016
18th Nov 20167:00 amRNSPresentation of REX Case Report at SCI Conference
7th Nov 20169:47 amRNSPositive Update from Rapper II Clinical Trial
24th Oct 20167:00 amRNSStroke & Brain Injury Clinical Trial in Australia
27th Sep 20161:00 pmRNSDirectors Interests
27th Sep 201612:57 pmRNSResults of Annual General Meeting
19th Sep 201610:57 amRNSRetirement of Director
1st Sep 20165:42 pmRNSPosting of Annual Report and Accounts
26th Aug 20167:00 amRNSAudited results for the year ended 31 March 2016
18th Aug 20167:00 amRNSMore Positive Data from RAPPER II
5th Aug 20162:14 pmRNSConfirmation of Strategic Investment by Maxhealth
1st Aug 201610:36 amRNSResults of General Meeting
22nd Jul 201612:00 pmRNSPosting of Supplementary Circular
18th Jul 20167:00 amRNSProposed Fundraising & General Meeting Adjournment
29th Jun 20169:30 amRNSProposed Fundraising and Notice of General Meeting
18th Mar 20162:30 pmRNSAppointment of Joint Broker
16th Mar 20167:00 amRNSTrading Update
11th Mar 20167:00 amRNSAgreement with the United States Army
19th Jan 20167:00 amRNSGrant of options
11th Jan 20167:00 amRNSJoseph A. Cucolo to join Rex Bionics Board
9th Dec 20156:04 pmRNSGrant of options
8th Dec 20157:00 amRNSInterim Results for 6 months ending 30 Sept 2015
27th Nov 20157:00 amRNSRex Bionics Positive Interim Data from RAPPER II
12th Oct 20157:00 amRNSRex Bionics Plc - Company Update
18th Sep 20157:00 amRNSLegal cases providing funding for REX
28th Aug 20157:00 amRNSResult of AGM
11th Aug 20159:54 amRNSHolding(s) in Company
10th Aug 20152:30 pmRNSHolding(s) in Company
4th Aug 20157:01 amRNSNew RexLink Software captures Robot Movement Data
20th Jul 20157:00 amRNSAnnouncement of partnership agreement with MAAB
8th Jul 20154:00 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
30th Jun 201511:31 amRNSResult of EGM
12th Jun 201511:06 amRNSProposed Fundraising and Notice of General Meeting
1st Jun 20157:00 amRNSFirst Patient Treated in RAPPER II Clinical Trial
29th May 20156:36 pmRNSCORRECTION Audited Results period ended31 Mar 2015
29th May 20154:25 pmRNSAudited results for period ending 31 Mar 2015
15th May 20157:00 amRNSRex announces Distribution Agreements in Europe
14th May 201510:00 amRNSREX to showcase at ISCoS and ASIA, Montreal
6th May 20157:02 amRNSMemorandum of Understanding signed
22nd Apr 20157:06 amRNSRex Bionics plc & Deltason establish partnership
15th Apr 20157:00 amRNSUpcoming Presentations to Private Investors
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.